Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: A prospective randomized clinical study

Giammaria Fiorentini; D. B. Poddie; M. Cantore; S. Rossi; S. Tumolo; P. Dentico; P. Bernardeschi; S. Guadagni; G. Rossi; V. M. Valori; M. De Simone

Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: A prospective randomized clinical study

Giammaria Fiorentini, D. B. Poddie, M. Cantore, S. Rossi, S. Tumolo, P. Dentico, P. Bernardeschi, S. Guadagni, G. Rossi, V. M. Valori, M. De Simone

Research output: Contribution to journal › Article › peer-review

Abstract

A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%. The median survival was 17 vs 11 months and the responses were 65% vs 33%. Toxicity was colangitis in 50% of patients considered. The extrahepatic progression was similar in the two groups (7/20 vs 8/22).

Original language	English
Pages (from-to)	51-54
Number of pages	4
Journal	Journal of Chemotherapy
Volume	16
Issue number	SUPPL. 5
Publication status	Published - Nov 2004

Keywords

Chemofiltration
Intra-arterial chemotherapy
Liver metastases

ASJC Scopus subject areas

Pharmacology (medical)
Microbiology (medical)

Fingerprint

Dive into the research topics of 'Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: A prospective randomized clinical study'. Together they form a unique fingerprint.

Cite this

Fiorentini, G., Poddie, D. B., Cantore, M., Rossi, S., Tumolo, S., Dentico, P., Bernardeschi, P., Guadagni, S., Rossi, G., Valori, V. M., & De Simone, M. (2004). Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: A prospective randomized clinical study. Journal of Chemotherapy, 16(SUPPL. 5), 51-54.

Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer : A prospective randomized clinical study. / Fiorentini, Giammaria; Poddie, D. B.; Cantore, M. et al.

In: Journal of Chemotherapy, Vol. 16, No. SUPPL. 5, 11.2004, p. 51-54.

Research output: Contribution to journal › Article › peer-review

Fiorentini, G, Poddie, DB, Cantore, M, Rossi, S, Tumolo, S, Dentico, P, Bernardeschi, P, Guadagni, S, Rossi, G, Valori, VM & De Simone, M 2004, 'Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: A prospective randomized clinical study', Journal of Chemotherapy, vol. 16, no. SUPPL. 5, pp. 51-54.

@article{682e25f155fb45b0a1e61e7e760c062b,

title = "Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: A prospective randomized clinical study",

abstract = "A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%. The median survival was 17 vs 11 months and the responses were 65% vs 33%. Toxicity was colangitis in 50% of patients considered. The extrahepatic progression was similar in the two groups (7/20 vs 8/22).",

keywords = "Chemofiltration, Intra-arterial chemotherapy, Liver metastases",

author = "Giammaria Fiorentini and Poddie, {D. B.} and M. Cantore and S. Rossi and S. Tumolo and P. Dentico and P. Bernardeschi and S. Guadagni and G. Rossi and Valori, {V. M.} and {De Simone}, M.",

year = "2004",

month = nov,

language = "English",

volume = "16",

pages = "51--54",

journal = "Journal of Chemotherapy",

issn = "1120-009X",

publisher = "Maney Publishing",

number = "SUPPL. 5",

}

TY - JOUR

T1 - Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer

T2 - A prospective randomized clinical study

AU - Fiorentini, Giammaria

AU - Poddie, D. B.

AU - Cantore, M.

AU - Rossi, S.

AU - Tumolo, S.

AU - Dentico, P.

AU - Bernardeschi, P.

AU - Guadagni, S.

AU - Rossi, G.

AU - Valori, V. M.

AU - De Simone, M.

PY - 2004/11

Y1 - 2004/11

N2 - A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%. The median survival was 17 vs 11 months and the responses were 65% vs 33%. Toxicity was colangitis in 50% of patients considered. The extrahepatic progression was similar in the two groups (7/20 vs 8/22).

AB - A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%. The median survival was 17 vs 11 months and the responses were 65% vs 33%. Toxicity was colangitis in 50% of patients considered. The extrahepatic progression was similar in the two groups (7/20 vs 8/22).

KW - Chemofiltration

KW - Intra-arterial chemotherapy

KW - Liver metastases

UR - http://www.scopus.com/inward/record.url?scp=19944426129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944426129&partnerID=8YFLogxK

M3 - Article

C2 - 15675479

AN - SCOPUS:19944426129

VL - 16

SP - 51

EP - 54

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - SUPPL. 5

ER -

Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: A prospective randomized clinical study

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this